 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > QLT Inc.
 |
QLT Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Xenova signs $105 mln deal for cancer drug Aug 13 2001 10:57 PM PDT
QLT shares dip a day after second-quarter earnings Jul 26 2001 11:30 AM PDT
QLT beats Q2 expectations for Visudyne sales Jul 25 2001 01:13 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
QLT's drugs respond to a light touch. The company focuses on pharmaceuticals that are activated when exposed to light. Visudyne, developed and marketed with Novartis Ophthalmics (once part of Novartis' CIBA Vision), fights a type of age-related macular degeneration (AMD), a leading cause of blindness. QLT's share of Visudyne sales accounts for about 75% of its revenues. The firm hopes to expand the drug's indications for other types of AMD, as well as for skin cancer and renarrowing of coronary arteries after angioplasty (restenosis, with partner Medtronic). It is developing photodynamic immunotherapy drugs with Corixa. QLT sold PHOTOFRIN, a cancer treatment it developed, to Canada's Axcan Pharma.
COMPETITION |
 |
Bausch & Lomb Incorporated (BOL)
DUSA Pharmaceuticals, Inc. (DUSA)
Miravant Medical Technologies (MRVT)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 32.80
1-Yr. Sales Growth: 81.2%
Employees: 350
Revenue per employee: $93,714.29
KEY PEOPLE |
 |
Julia G. Levy
CEO
Janice Stasiuk
CFO
CONTACT INFO |
 |
887 Great Northern Way
Vancouver British Columbia V5T 4T5, Canada
Phone: 1-604-872-7881
Fax: 1-604-875-0001
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |